In Mice with Scleroderma, Cannabinoid-derived Therapies Slow Fibrosis

Emerald Health’s lead cannabinoid-derived investigational therapy, EHP-101, shows promise as a possible oral treatment for scleroderma, a mouse study shows.

A second cannabinoid-derivative, called VCE-004.3, also showed potential to enhance anti-inflammatory and anti-fibrotic responses in animal models of scleroderma.

Both EHP-101 and VCE-004.3 are derived from cannabidiol (CBD), one of the natural chemicals extracted from the cannabis plant.

EHP-101 is an oral formulation of VCE-004.8, the original cannabinoid-derivative that was previously shown to alleviate fibrosis when injected in a mouse model of skin fibrosis.

The therapies target and activate two receptors, called peroxisome proliferator-activated receptor gamma (PPAR-γ) and CB2 receptors, increasingly recognized for their potential to prevent inflammation and fibrosis.

In the study “EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis,” published in the journal Biochemical Pharmacology, researchers tested whether oral EHP-101 maintained the same therapeutic properties as VCE-004.8.

Researchers used a

... read more at: https://sclerodermanews.com/2018/09/25/cannabinoid-derived-therapies-slow-fibrosis-block-inflammation-mice-scleroderma/